30 0

Full metadata record

DC FieldValueLanguage
dc.contributor.author이혜순-
dc.date.accessioned2019-11-26T05:25:40Z-
dc.date.available2019-11-26T05:25:40Z-
dc.date.issued2017-06-
dc.identifier.citationRHEUMATOLOGY INTERNATIONAL, v. 37, no. 6, page. 1007-1014en_US
dc.identifier.issn0172-8172-
dc.identifier.issn1437-160X-
dc.identifier.urihttps://link.springer.com/article/10.1007%2Fs00296-017-3663-z-
dc.identifier.urihttp://repository.hanyang.ac.kr/handle/20.500.11754/114590-
dc.description.abstractTo compare the characteristics of rheumatoid arthritis (RA) patients receiving either biosimilar or originator infliximab and to identify the effectiveness and safety of biosimilar infliximab in RA patients in real-world practice. RA patients who started either biosimilar or originator infliximab were selected using the prospective biologic disease-modifying anti-rheumatic drugs (DMARDs) registry: BIOlogics Pharmacoepidemiologic StudY (BIOPSY). Baseline characteristics of the two groups were compared, and short-term treatment outcomes, including DAS28-ESR and HAQ-DI scores, were compared after initiation of biosimilar or originator infliximab. The drug retention rates of the two groups were also compared. A total of 100 RA patients, 55 biosimilar, and 45 originator infliximab users were included in this analysis. Baseline characteristics of age, disease duration, and previous or current medications were similar in the two groups. Baseline DAS28-ESR was higher in the originator infliximab group (6.3 +/- 1.1 vs. 5.8 +/- 1.1, p = 0.02). The early DAS28-ESR remission rates observed 7.9 +/- 1.8 months after starting biosimilar and originator infliximab were 15.0 and 25.0%, respectively (p = 0.47). The change in HAQ-DI did not differ between the two groups (0.4 +/- 0.7 vs. 0.4 +/- 0.8, p = 0.94). Patients treated with biosimilar infliximab in clinical practice had lower disease activity at the start of treatment than those receiving originator infliximab. Biosimilar infliximab was well-tolerated, safe, and of similar clinical effectiveness to originator infliximab. Larger number of patient and longer follow-up data will be needed to confirm the effectiveness and safety of biosimilar infliximab in clinical practice.en_US
dc.description.sponsorshipThis research was supported by a grant from the Korea Health Technology R&D Project through the Korea Health Industry Development Institute (KHIDI), funded by the Ministry of Health & Welfare, Republic of Korea (Grant Number: HI16C0061).en_US
dc.language.isoen_USen_US
dc.publisherSPRINGER HEIDELBERGen_US
dc.subjectRheumatoid arthritisen_US
dc.subjectBiologic DMARDsen_US
dc.subjectBiosimilaren_US
dc.subjectEffectivenessen_US
dc.subjectSafetyen_US
dc.titleCharacteristics and outcomes of rheumatoid arthritis patients who started biosimilar infliximaben_US
dc.typeArticleen_US
dc.relation.no6-
dc.relation.volume37-
dc.identifier.doi10.1007/s00296-017-3663-z-
dc.relation.page1007-1014-
dc.relation.journalRHEUMATOLOGY INTERNATIONAL-
dc.contributor.googleauthorSung, Yoon-Kyoung-
dc.contributor.googleauthorCho, Soo-Kyung-
dc.contributor.googleauthorKim, Dam-
dc.contributor.googleauthorWon, Soyoung-
dc.contributor.googleauthorChoi, Chan-Bum-
dc.contributor.googleauthorBang, So-Young-
dc.contributor.googleauthorHong, Seung-Jae-
dc.contributor.googleauthorKim, Hyoun Ah-
dc.contributor.googleauthorKoh, Eun-Mi-
dc.contributor.googleauthorLee, Hye-Soon-
dc.relation.code2017003720-
dc.sector.campusS-
dc.sector.daehakCOLLEGE OF MEDICINE[S]-
dc.sector.departmentDEPARTMENT OF MEDICINE-
dc.identifier.pidlhsberon-
Appears in Collections:
COLLEGE OF MEDICINE[S](의과대학) > MEDICINE(의학과) > Articles
Files in This Item:
There are no files associated with this item.
Export
RIS (EndNote)
XLS (Excel)
XML


qrcode

Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.

BROWSE